| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:54 UTC |
|---|
| HMDB ID | HMDB0015235 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Quinacrine |
|---|
| Description | quinacrine, also known as mepacrine, belongs to the class of organic compounds known as acridines. These are organic compounds containing the acridine moiety, a linear tricyclic heterocycle which consists of two benzene rings joined by a pyridine ring. Based on a literature review a small amount of articles have been published on quinacrine. |
|---|
| Structure | CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=C1C=CC(Cl)=C2 InChI=1S/C23H30ClN3O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26) |
|---|
| Synonyms | | Value | Source |
|---|
| 2-Methoxy-6-chloro-9-diethylaminopentylaminoacridine | ChEBI | | 3-Chloro-7-methoxy-9-(1-methyl-4-diethylaminobutylamino)acridine | ChEBI | | 6-Chloro-9-((4-(diethylamino)-1-methylbutyl)amino)-2-methoxyacridine | ChEBI | | Mepacrine | ChEBI | | N(4)-(6-Chloro-2-methoxy-9-acridinyl)-N(1),N(1)-diethyl-1,4-pentanediamine | ChEBI | | Quinacrin | Kegg | | Quinacrine dihydrochloride | HMDB, MeSH | | Monomesylate, quinacrine | MeSH, HMDB | | Quinacrine dimesylate | MeSH, HMDB | | Quinacrine, (R)-isomer | MeSH, HMDB | | Acrichine | MeSH, HMDB | | Dihydrochloride, quinacrine | MeSH, HMDB | | Dimesylate, quinacrine | MeSH, HMDB | | Quinacrine hydrochloride | MeSH, HMDB | | Quinacrine monoacetate | MeSH, HMDB | | Quinacrine monomesylate | MeSH, HMDB | | Atebrin | MeSH, HMDB | | Monohydrochloride, quinacrine | MeSH, HMDB | | Quinacrine dihyrochloride, (S)-isomer | MeSH, HMDB | | Quinacrine monohydrochloride | MeSH, HMDB | | Quinacrine, (+-)-isomer | MeSH, HMDB | | Quinacrine, (S)-isomer | MeSH, HMDB | | Atabrine | MeSH, HMDB | | Hydrochloride, quinacrine | MeSH, HMDB | | Monoacetate, quinacrine | MeSH, HMDB | | Quinacrine dihydrochloride, dihydrate | MeSH, HMDB | | Quinacrine dihyrochloride, (R)-isomer | MeSH, HMDB |
|
|---|
| Chemical Formula | C23H30ClN3O |
|---|
| Average Molecular Weight | 399.957 |
|---|
| Monoisotopic Molecular Weight | 399.207740304 |
|---|
| IUPAC Name | 6-chloro-N-[5-(diethylamino)pentan-2-yl]-2-methoxyacridin-9-amine |
|---|
| Traditional Name | 6-chloro-N-[5-(diethylamino)pentan-2-yl]-2-methoxyacridin-9-amine |
|---|
| CAS Registry Number | 83-89-6 |
|---|
| SMILES | CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=C1C=CC(Cl)=C2 |
|---|
| InChI Identifier | InChI=1S/C23H30ClN3O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26) |
|---|
| InChI Key | GPKJTRJOBQGKQK-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as acridines. These are organic compounds containing the acridine moiety, a linear tricyclic heterocycle which consists of two benzene rings joined by a pyridine ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Quinolines and derivatives |
|---|
| Sub Class | Benzoquinolines |
|---|
| Direct Parent | Acridines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Acridine
- Haloquinoline
- Chloroquinoline
- Anisole
- Alkyl aryl ether
- Aryl chloride
- Aryl halide
- Pyridine
- Benzenoid
- Secondary ketimine
- Heteroaromatic compound
- Tertiary aliphatic amine
- Tertiary amine
- Ether
- Azacycle
- Amine
- Organooxygen compound
- Organonitrogen compound
- Organochloride
- Organohalogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 248 - 250 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.0024 g/L | Not Available | | LogP | 5.5 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 6.62 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.0907 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.04 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 109.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Quinacrine,1TMS,isomer #1 | CCN(CC)CCCC(C)N(C1=C2C=CC(Cl)=CC2=NC2=CC=C(OC)C=C12)[Si](C)(C)C | 3163.2 | Semi standard non polar | 33892256 | | Quinacrine,1TMS,isomer #1 | CCN(CC)CCCC(C)N(C1=C2C=CC(Cl)=CC2=NC2=CC=C(OC)C=C12)[Si](C)(C)C | 2820.3 | Standard non polar | 33892256 | | Quinacrine,1TMS,isomer #1 | CCN(CC)CCCC(C)N(C1=C2C=CC(Cl)=CC2=NC2=CC=C(OC)C=C12)[Si](C)(C)C | 3866.6 | Standard polar | 33892256 | | Quinacrine,1TBDMS,isomer #1 | CCN(CC)CCCC(C)N(C1=C2C=CC(Cl)=CC2=NC2=CC=C(OC)C=C12)[Si](C)(C)C(C)(C)C | 3336.3 | Semi standard non polar | 33892256 | | Quinacrine,1TBDMS,isomer #1 | CCN(CC)CCCC(C)N(C1=C2C=CC(Cl)=CC2=NC2=CC=C(OC)C=C12)[Si](C)(C)C(C)(C)C | 3077.7 | Standard non polar | 33892256 | | Quinacrine,1TBDMS,isomer #1 | CCN(CC)CCCC(C)N(C1=C2C=CC(Cl)=CC2=NC2=CC=C(OC)C=C12)[Si](C)(C)C(C)(C)C | 3927.0 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Quinacrine GC-MS (Non-derivatized) - 70eV, Positive | splash10-000i-9025000000-fbef6d955948eb7f2a3f | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Quinacrine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Quinacrine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Quinacrine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine LC-ESI-QTOF , negative-QTOF | splash10-0002-0009200000-6e09844cb8551172f45c | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine LC-ESI-QTOF , negative-QTOF | splash10-0002-0009200000-242960dc93e3658182f0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine LC-ESI-QTOF , negative-QTOF | splash10-0002-0019100000-85abeddd06ff2cce1fc9 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine LC-ESI-QTOF , positive-QTOF | splash10-0udi-0000900000-171d21b8fffe35f493d3 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine LC-ESI-QTOF , positive-QTOF | splash10-0udl-0423900000-9f5ab94c444b1766bd01 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine LC-ESI-QTOF , positive-QTOF | splash10-0006-0934000000-afa177ceaf2f17c89180 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine LC-ESI-QTOF , positive-QTOF | splash10-0006-0964000000-cb8056f84bdb3a200fba | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine LC-ESI-QTOF , positive-QTOF | splash10-0006-0591000000-00e303f9525d62f012d4 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine 10V, Positive-QTOF | splash10-0udi-0000900000-171d21b8fffe35f493d3 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine 20V, Positive-QTOF | splash10-0udl-0423900000-9f5ab94c444b1766bd01 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine 40V, Positive-QTOF | splash10-0006-0964000000-cb8056f84bdb3a200fba | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine 30V, Positive-QTOF | splash10-0006-0934000000-afa177ceaf2f17c89180 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine 20V, Negative-QTOF | splash10-0002-0009200000-242960dc93e3658182f0 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine 30V, Negative-QTOF | splash10-0002-0019100000-85abeddd06ff2cce1fc9 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine 10V, Negative-QTOF | splash10-0002-0009200000-6e09844cb8551172f45c | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine 50V, Positive-QTOF | splash10-0006-0591000000-00e303f9525d62f012d4 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine 50V, Positive-QTOF | splash10-0006-0591000000-ec7a34b139a1f19af5f1 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinacrine 20V, Positive-QTOF | splash10-0002-0009200000-d6edfe4dda8af03dcf55 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinacrine 10V, Positive-QTOF | splash10-0udi-0002900000-f41646003acc390ed8bb | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinacrine 20V, Positive-QTOF | splash10-0zfu-4975600000-ad273f8cfc82a9f76e9e | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinacrine 40V, Positive-QTOF | splash10-009f-9251000000-556ea0aa9d5a370006a7 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinacrine 10V, Negative-QTOF | splash10-0002-0009000000-b9379b7c57314e49af30 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinacrine 20V, Negative-QTOF | splash10-0002-0019000000-79e7dea5a1914a86d008 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinacrine 40V, Negative-QTOF | splash10-00di-9065000000-35833408615f0d3aa74a | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinacrine 10V, Positive-QTOF | splash10-0udi-0000900000-f4b3bd614216642b1025 | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Bhatt RV: Camp laparoscopic sterilization deaths in Gujarat State, India, 1978-1980. Asia Oceania J Obstet Gynaecol. 1991 Dec;17(4):297-301. [PubMed:1839351 ]
- Zipper J, Cole LP, Goldsmith A, Wheeler R, Rivera M: Quinacrine hydrochloride pellets: preliminary data on a nonsurgical method of female sterilization. Int J Gynaecol Obstet. 1980;18(4):275-9. [PubMed:6109672 ]
- Peterson HB, Lubell I, DeStefano F, Ory HW: The safety and efficacy of tubal sterilization: an international overview. Int J Gynaecol Obstet. 1983 Apr;21(2):139-44. [PubMed:6136433 ]
- Toubi E, Kessel A, Rosner I, Rozenbaum M, Paran D, Shoenfeld Y: The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. Scand J Immunol. 2006 Apr;63(4):299-303. [PubMed:16623930 ]
- Canete R, Escobedo AA, Gonzalez ME, Almirall P: Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children. World J Gastroenterol. 2006 Oct 21;12(39):6366-70. [PubMed:17072963 ]
|
|---|